<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01878123</url>
  </required_header>
  <id_info>
    <org_study_id>AMP-110-01</org_study_id>
    <nct_id>NCT01878123</nct_id>
  </id_info>
  <brief_title>Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-110 in Subjects With Rheumatoid Arthritis</brief_title>
  <official_title>A Randomized, Single-Dose, Placebo-Controlled, Study of the Safety, Tolerability, and Pharmacokinetics of AMP-110 in Subjects With Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Daiichi Sankyo Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>MedImmune LLC</source>
  <brief_summary>
    <textblock>
      This is a Phase 1, single-dose, placebo-controlled, dose-escalation,multi-center, first time
      in human study of AMP-110 in adult subjects with rheumatoid arthritis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the safety and tolerability of a single dose of AMP-110 versus placebo</measure>
    <time_frame>From start of study drug administration through Day 56</time_frame>
    <description>Evaluate number of subjects with dose-limiting toxicities (through Day 14), evaluate number of subjects wtih adverse events (through Day 56), and number of subjects wtih changes from baseline in laboratory values, vital signs, physical exam and electrocardiogram (through Day 56)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine Maximum Tolerated Dose and/or recommended dose level(s) for future clinical trials</measure>
    <time_frame>From start of study drug administration through Day 56</time_frame>
    <description>Based on the occurrence of dose-limiting toxicities (through Day 14)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate pharmacokinetic profile of a single dose of AMP-110</measure>
    <time_frame>From Day 0 pre-dose through Day 28</time_frame>
    <description>Pharmacokinetics evaluated by area under the serum concentration versus time curve (AUC), peak serum concentration (Cmax), and clearance (Cl) of AMP-110</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Assess pharmacokinetic and pharmacodynamic relationships</measure>
    <time_frame>From Day 0 pre-dose through Day 56</time_frame>
    <description>Determine if pharmacodynamics effects of AMP-110 on certain cytokine levels and T cell subsets are dependent on serum drug concentrations</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluate exploratory biomarkers</measure>
    <time_frame>From start of study drug administration through Day 56</time_frame>
    <description>Blood samples will be analyzed throughout the study to characterize the physiological effects of AMP-110 treatment and to determine markers that correlate with response to treatment</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>AMP-110</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalating doses of AMP-110</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AMP-110</intervention_name>
    <description>Dose levels 1 through 7: Single intravenous infusion on Day 0</description>
    <arm_group_label>AMP-110</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Dose levels 4 through 7: Single intravenous infusion on Day 0</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be able to provide written informed consent

          -  Body mass index 18.5 to 35.0 kg/m2

          -  Diagnosis of Rheumatoid Arthritis according to 1987 revised American College of
             Rheumatology (ACR) criteria

          -  Global Functional Class I, II, or III according to ACR 1991 revised criteria

          -  Stable use of &gt;/= 1 Disease Modifying Anti-rheumatic Drugs (DMARD) for &gt;/= 4 weeks
             prior to Day 0, including:

               1. Methotrexate (MTX) 7.5 - 25 mg/week

               2. Hydroxychloroquine (HCQ) &lt;/= 400 mg/day

               3. Sulfasalazine (SSZ) 1,000 - 3,000 mg/day

               4. Leflunomide 5 - 20 mg/day

               5. Azathioprine 150 mg/day or 2 mg/kg/day

               6. Combinations of MTX, HCQ, and/or SSZ allowed

        Exclusion Criteria:

          -  Prior to Day 0, use of

               1. Abatacept

               2. Rituximab within 6 months

               3. Infliximab, Adalimumab, Certolizumab, Tocilizumab, Cyclosporine, or Mycophenolate
                  mofetil within 2 months

               4. Etanercept or Anakinra within 28 days

               5. Immunoglobulin or blood products within 28 days

          -  Evidence of any active or recent infection including ongoing, chronic infectious
             disease such as chronic renal infection or chronic chest infection with bronchiectasis
             or sinusitis

          -  History of systemic autoimmune disease other than Rheumatoid Arthritis

          -  History of allergic reactions to other protein therapeutics such as monoclonal
             antibodies or fusion proteins

          -  History of anaphylaxis or allergic diathesis

          -  Clinically significant cardiac disease, including: unstable angina; myocardial
             infarction within 6 months; congestive heart failure; arrhythmia requiring active
             therapy, with the exception of clinically insignificant extrasystoles, or minor
             conduction abnormalities; and history of clinically significant abnormality on
             electrocardiogram

          -  Evidence of active or latent tuberculosis

          -  Vaccination wtih live attenuated viruses within the 2 weeks prior to Day 0

          -  Evidence of infection with hepatitis B virus, hepatitis C virus, human
             immunodeficiency virus 1 or 2, or active infection with hepatitis A

          -  Pregnant or breastfeeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Pinnacle Research Group, LLC</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altoona Center for Clinical Research</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metroplex Clinical Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2013</study_first_submitted>
  <study_first_submitted_qc>June 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2013</study_first_posted>
  <last_update_submitted>September 29, 2016</last_update_submitted>
  <last_update_submitted_qc>September 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Arthritis</keyword>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>Joint Diseases</keyword>
  <keyword>Musculoskeletal Diseases</keyword>
  <keyword>Rheumatic Diseases</keyword>
  <keyword>Connective Tissue Diseases</keyword>
  <keyword>Autoimmune Diseases</keyword>
  <keyword>Immune System Diseases</keyword>
  <keyword>Antirheumatic agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

